Key result
Capecitabine-induced hypertriglyceridemia was observed in 10% of treated patients, indicating it is not a rare adverse effect and requires lipid profile monitoring.
Why the study?
Does capecitabine treatment cause hypertriglyceridemia in cancer patients?
Observational
Does capecitabine treatment cause hypertriglyceridemia in cancer patients?
Capecitabine-induced hypertriglyceridemia occurs in approximately 10% of treated patients, highlighting the need for routine lipid profile monitoring during therapy.
Capecitabine is an oral fluoropyrimidine which is transformed to 5-Fluorouracil inside tumor cells, where it achieves high drug concentrations. Capecitabine is an active drug diffusely utilized in the treatment of various types of tumors, such as breast, colorectal, gastric, head and neck carcinoma. In our experience, capecitabine-induced hypertriglyceridemia does not seem to be a rare adverse effect as it is observed in 10% of treated patients. It is necessary to monitor the lipidic profile of patients treated with capecitabine also in consideration of the frequent presence of comorbidities in cancer populations, the concomitant toxicity related to other drugs used in combination regimens, and cardiovascular effects characteristic of biological target therapy.
No takes yet. Share an insight, caveat, or question.
Seminara et al. (2010) conducted an observational in Cancer. Capecitabine was evaluated on Hypertriglyceridemia. Capecitabine-induced hypertriglyceridemia was observed in 10% of treated patients, indicating it is not a rare adverse effect and requires lipid profile monitoring.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: